^ WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a
global biopharmaceutical company aiming to play a leading role in the
Development and commercialization of inflammatory and immunology therapies
announced today the appointment of Patricia Allen to the Board of Directors of
company, where she also served as chairwoman of the audit committee
will function. Ms. Allen will have more than 20 years of experience in the
areas of finance, investor relations, business development, human resources,
Operations and IT in global listed and private companies
Bring biotechnology companies onto Zenas’ board of directors.
“We are pleased to welcome Ms. Allen to our Board of Directors,” said
Lonnie Moulder, founder and chairman of Zenas BioPharma.
?She has successfully led cross-organizational functions and was in
Board of directors of private and listed global companies
biotechnology company. We look forward to Ms. Allen’s contribution to the
Zenas next phase of growth as we advance our mission,
to develop and deliver transformative immunological therapies for patients
market those who urgently need it.”
“I am looking forward to working with the experienced team at Zenas and the
Board of Directors, through disciplined implementation of the pipeline and
Business development a leader in inflammation and immunology
“To build a focused global biopharmaceutical company,” said Ms. Allen.?This
is an exciting time for Zenas as the company is currently attempting to achieve several
Advance programs in the clinic to ultimately save people’s lives
with autoimmune diseases.”
Ms. Allen most recently served as Chief Financial Officer at Vividion Therapeutics
where she recently left. During her time at Vividion she led
the fundraising and the takeover of the company by Bayer AG,
as the company grew and several programs toward the clinic
propulsion. She is currently a member of the board of directors and chairwoman of the
Audit Committee of Deciphera Pharmaceuticals, SwanBio Therapeutics and
Anokion. In addition, she was a member of the in the past
Board of Directors and Chair of the Audit Committee of Inversago Pharma and
Yumanity Therapeutics.
Prior to joining Vividion, Ms. Allen held the position of Chief
Financial Officer at Zafgen, Inc. (now Larimer Therapeutics). Previously was
She is Vice President of Finance and Treasurer, Principal Financial Officer
Alnylam Pharmaceuticals, Inc. and Director of Finance at Alkermes, Inc. and
Auditor at Deloitte & Touche, LLP. She holds a BS degree
in Business Administration from Bryant College.
About Zenas BioPharma
Zenas BioPharma is a global biopharmaceutical company focused on…
The goal is to become a leading company in development and marketing
of inflammation and immunology-oriented therapies for urgent need
to become trusted patients all over the world. Zenas has clinical
Development capacities and operates worldwide to potentially create a portfolio
differentiated autoimmune therapeutics in areas with high medical needs
to develop needs. We use our experience and skills
Leadership teams and our established networks in the biopharmaceutical industry
Developing therapies that improve the lives of people with autoimmune diseases
and rare diseases. For more information about Zenas
BioPharma please visit www.zenasbio.com (http://www.zenasbio.com/) and
follow us on X (formerly Twitter) at @ZenasBioPharma
(https://twitter.com/ZenasBioPharma) and LinkedIn
(https://www.linkedin.com/company/zenas-biopharma/).
Investor and media contact:
Argot Partners
[email protected] (mailto:[email protected])
°